Advertisement

Topics

Search Results for "Neupro"

09:40 EDT 1st May 2016 | BioPortfolio

Matching Channels

None

Matching News

UCB gains after boosting guidance

UCB Group (Euronext:UCB) gained EUR 4.29 to EUR 75.81 on Wednesday after reporting 3Q15 earnings and raising its guidance for 2015. The company raised its revenue guidance to EUR 3.75 billion ($4.14 b...

BRIEF-UCB posts FY REBIT ahead of Reuters poll

* FY revenue and net sales increased driven by product growth: Cimzia, Vimpat, Neupro and Keppra combined reached net sales of 2.76 billion euros ($3.05 billion) (+29 pct); representing 77 pct of net...

Cimzia and epilepsy drugs fuel UCB growth

Strong performances from its flagship products have lifted revenues of specialist pharma company UCB.The Belgium-headquartered firm announced its 2015 results late last week, with reven...

Parkinson's Disease Market Will Exceed $3 Billion by 2021 Despite Little Advance Towards a Cure, Says GBI Research

LONDON, February 25, 2016 /PRNewswire/ -- A new report from business intelligence provider GBI Research - Parkinson's Disease Therapeutics in Major Developed Markets to 2021 - states that the Parkins...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement